Advances in the pharmacotherapy of alcoholism: Challenging misconceptions

Alcoholism: Clinical and Experimental Research

Volumn 30, Issue 2, 2006, Pages 272-281

  Kranzler, Henry R ^a,b   Koob, George ^c   Gastfriend, David R ^d   Swift, Robert M ^e,f   Willenbring, Mark L ^g  

^a University of Connecticut Health Center ^*  (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e ALKERMES INC   (United States)

^f BROWN UNIVERSITY   (United States)

^g NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Alcohol Dependence; Alcoholism Treatment; Medications Development; Pharmacotherapy

Indexed keywords

ACAMPROSATE; AMINO ACID DERIVATIVE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; DISULFIRAM; DOPAMINE RECEPTOR STIMULATING AGENT; KAPPA OPIATE RECEPTOR ANTAGONIST; MU OPIATE RECEPTOR ANTAGONIST; NALTREXONE; OPIATE ANTAGONIST; TOPIRAMATE;

ALCOHOL WITHDRAWAL; ALCOHOLISM; CLINICAL TRIAL; CONFERENCE PAPER; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL RESEARCH; MIGRAINE; NEUROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SEIZURE; UNSPECIFIED SIDE EFFECT;

ALCOHOL DETERRENTS; ALCOHOLISM; AMYGDALA; ANIMALS; BRAIN; CORTICOTROPIN-RELEASING HORMONE; HUMANS; MOTIVATION; NEUROTRANSMITTER AGENTS; NUCLEUS ACCUMBENS; PATIENT ACCEPTANCE OF HEALTH CARE; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 33644750402     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2006.00022.x     Document Type: Conference Paper

References (46)

1. American Psychiatric Association 1994 Diagnostic and Statistical Manual of Mental Disorders 4th ed American Psychiatric Press Washington, DC
2. Anton RF Swift RM 2003 Current pharmacotherapies of alcoholism a U S perspective Am J Addict 12 suppl. 1 S53 S68
3. Aston-Jones G Delfs JM Druhan J Zhu Y 1999 The bed nucleus of the stria terminalis a target site for noradrenergic actions in opiate withdrawal In Annals of the New York Academy of Sciences, Vol. 877, Advancing from the Ventral Striatum to the Extended Amygdala: Implications for Neuropsychiatry and Drug Abuse McGinty JF ed), pp 486 498 New York Academy of Sciences New York
4. Bachteler D Economidou D Danysz W Ciccocioppo R Spanagel R 2005 The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat Neuropsychopharmacology 30 1104 1110
5. Bouza C Angeles M Munoz A Amate JM 2004 Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence a systematic review Addiction 99 811 828
6. Chick J Lehert P Landron F Plinius Major Society 2003 Does acamprosate improve reduction of drinking as well as aiding abstinence? J Psychopharmacol 17 397 402
7. Combine Study Research Group 2003 Testing combined pharmacotherapies and behavioral interventions in alcohol dependence rationale and methods Alcohol Clin Exp Res 27 1107 1122
8. Feinn R Kranzler HR 2005 Does effect size in naltrexone trials for alcohol dependence differ for single-site vs. multi-center studies? Alcohol Clin Exp Res 29 983 988
9. Fuller RK Branchey L Brightwell DR Derman RM Emrick CD Iber FL James KE Lacoursiere RB Lee KK Lowenstam I et al 1986 Disulfiram treatment of alcoholism a Veteran's Administration Cooperative Study JAMA 256 1449 1455
10. ® Study Group 2005 Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence a randomized controlled trial JAMA 293 1617 1625
11. Grant BF Dawson DA Stinson FS Chou SP Dufour MC Pickering RP 2004a The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence United States, 1991-1992 and 2001-2002 Drug Alcohol Depend 74 223 234
12. Grant BF Stinson FS Dawson DA Chou SP Dufour MC Compton W Pickering RP Kaplan K 2004b Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders results from the national epidemiologic survey on alcohol and related conditions (NESARC) Arch Gen Psychiatry 61 807 816
13. Heyser CJ Schulteis G Durbin P Koob GF 1998 Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats Neuropsychopharmacology 18 125 133
14. Johnson BA Ait-Daoud N Bowden CL DiClemente CC Roache JD Lawson K Javors MA Ma JZ 2003 Oral topiramate for treatment of alcohol dependence a randomized controlled trial Lancet 361 1677 1685
15. Kiefer F Jahn H Tarnaske T Helwig H Briken P Holzbach R Kampf P Stracke R Baehr M Naber D Wiedemann K 2003 Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism a double-blind, placebo-controlled study Arch Gen Psychiatry 60 92 99
16. Koob GF 2003 Alcoholism allostasis and beyond Alcohol Clin Exp Res 27 232 243
17. Koob GF Bloom FE 1988 Cellular and molecular mechanisms of drug dependence Science 242 715 723
18. Koob GF Le Moal M 1997 Drug abuse hedonic homeostatic dysregulation Science 278 52 58
19. Koob GF Le Moal M 2001 Drug addiction, dysregulation of reward, and allostasis Neuropsychopharmacology 24 97 129
20. Koob GF Roberts AJ Kieffer BL Heyser CJ Katner SN Ciccocioppo R Weiss F 2003 Animal models of motivation for drinking in rodents with a focus on opioid receptor neuropharmacology In Recent Developments in Alcoholism, Vol. 16, Research on Alcoholism Treatment Galanter M ed), pp 263 281 Plenum Press New York
21. Kranzler HR Armeli S Tennen H Blomqvist O Oncken C Petry N Feinn R 2003 Targeted naltrexone for early problem drinkers J Clin Psychopharmacol 23 294 304
22. Kranzler HR Wesson DR Billot L 2004 Naltrexone depot for treatment of alcohol dependence a multicenter, randomized, placebo-controlled clinical trial Alcohol Clin Exp Res 28 1051 1059
23. Liu X Weiss F 2002 Additive effect of stress and drug cues on reinstatement of ethanol seeking exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms J Neurosci 22 7856 7861
24. Mann K 2004 Pharmacotherapy of alcohol dependence a review of the clinical data CNS Drugs 18 485 504
25. Mark TL Kranzler HR Poole VH Hagen CA McLeod C Crosse S 2003b Barriers to the use of medications to treat alcoholism Am J Addict 12 281 294
26. Mark TL Kranzler HR Song X Bransberger P Poole VH Crosse S 2003a Physicians' opinions about medications to treat alcoholism Addiction 98 617 626
27. McGlynn EA Asch SM Adams J Keesey J Hicks J DeCristofaro A Kerr EA 2003 The quality of health care delivered to adults in the United States N Engl J Med 348 2635 2645
28. McLellan AT Meyers K 2004 Contemporary addiction treatment a review of systems problems for adults and adolescents Biol Psychiatry 56 764 770
29. Meyer R 1989 Prospects for a rational pharmacotherapy of alcoholism J Clin Psychiatry 50 403 412
30. Miller WR Andrews NR Wilbourne P Bennett ME 1998 Wealth of alternatives effective treatments for alcohol problems In Treating Addictive Behaviors 357 2nd ed Miller WR Heather N eds), pp 203 216 Plenum Press New York
31. Miller WR Walters ST Bennett ME 2001 How effective is alcoholism treatment in the United States? J Stud Alcohol 62 211 220
32. Mokdad AH Marks JS Stroup DF Gerberding JL 2004 Actual causes of death in the United States, 2000 JAMA 291 1238 1245
33. Morse AC Koob GF 2002 Intra-BNST acamprosate attenuates withdrawal-induced increases in ethanol consumption in dependents rats Society Neurosci Abstr 28 783 784
34. Nestler EJ 2001 Molecular basis of long-term plasticity underlying addiction Nat Rev Neurosci 2 119 128
35. O'Malley SS Jaffe AJ Chang G Schottenfeld RS Meyer RE Rounsaville B 1992 Naltrexone and coping skills therapy for alcohol dependence a controlled study Arch Gen Psychiatry 49 881 887
36. Piazza PV Le Moal M 1996 Pathophysiological basis of vulnerability to drug abuse role of an interaction between stress, glucocorticoids, and dopaminergic neurons Annu Rev Pharmacol Toxicol 36 359 378
37. Prochaska JO Velicer WF Rossi JS Goldstein MG Marcus BH Rakowski W Fiore C Harlow LL Redding CA Rosenbloom D Rossi SR 1994 Stages of change and decisional balance for 12 problem behaviors Health Psychol 13 39 46
38. Rychtarik RG Connors GJ Dermen KH Stasiewicz PR 2000 Alcoholics Anonymous and the use of medications to prevent relapse an anonymous survey of member attitudes J Stud Alcohol 61 134 138
39. Shaham Y Erb S Stewart J 2000 Stress-induced relapse to heroin and cocaine seeking in rats a review Brain Res Rev 33 13 33
40. Shippenberg TS Koob GF 2002 Recent advances in animal models of drug addiction and alcoholism In Neuropsychopharmacology: the Fifth Generation of Progress Davis KL Charney D Coyle JT Nemeroff C eds), pp 1381 1397 Lippincott Williams and Wilkins Philadelphia
41. Spanagel R Hölter SM Allingham K Landgraf R Zieglgänsberger W 1996a Acamprosate and alcohol I. Effects on alcohol intake following alcohol deprivation in the rat Eur J Pharmacol 305 39 44
42. Spanagel R Putzke J Stefferl A Schobitz B Zieglgansberger W 1996b Acamprosate and alcohol II. Effects on alcohol withdrawal in the rat Eur J Pharmacol 305 45 50
43. Swift RM Nirenberg T Femino J 1998 Alcoholic patients attitudes and experience toward pharmacotherapy for alcoholism J Addict Dis 17 35 47
44. Thomas C Wallack S Swift R Bishop C McCarty D Simoni-Wastila L 2003 Research to practice adoption of naltrexone in alcoholism treatment J Subst Abuse Treat 24 1 11
45. Valdez GR Roberts AJ Chan K Davis H Brennan M Zorrilla EP Koob GF 2002 Increased ethanol self-administration and anxiety-like behavior during acute withdrawal and protracted abstinence regulation by corticotropin-releasing factor Alcohol Clin Exp Res 26 1494 1501
46. Volpicelli J Alterman AI Hayashida M O'Brien CP 1992 Naltrexone in the treatment of alcohol dependence Arch Gen Psychiatry 49 876 880